FAP and thyroid gland carcinoma: Another agent with the FAP-binding scaffold conjugated to ethylene blue (an albumin binder that increases circulation time), 177Lu-EB-FAPI (also known as 177Lu-LNC1004), was tested in a cohort of twelve patients with differentiated thyroid cancer and showed partial response in three patients and stable disease in another seven [30].